Merck’s Keytruda plus chemotherapy meets OS and PFS goals in KEYNOTE-590 trial

This article was originally published here

In the study, KEYTRUDA in combination with chemotherapy significantly improved overall survival (OS), reducing the risk of death by 27% [HR=0.73 [95% CI, 0.62-0.86]; p<0.0001], versus chemotherapy in

The post Merck’s Keytruda plus chemotherapy meets OS and PFS goals in KEYNOTE-590 trial appeared first on Pharmaceutical Business review.